UPMC Hillman Cancer Center | Strategic Alliance Partners

June 04, 2020

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

May 12, 2020

Adam M. Brufsky, MD, PhD, discusses the impact of the COVID-19 pandemic on patients with cancer, as well as the science behind the proposed explanation of the immunopathology of COVID-19.

April 30, 2020

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

April 28, 2020

Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.

April 24, 2020

Adam M. Brufsky, MD, PhD, highlightes the treatment landscape in HER2-positive breast cancer, remaining sequencing questions, and the growing utility of neratinib in the paradigm.

April 22, 2020

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

April 13, 2020

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

April 10, 2020

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

April 09, 2020

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

April 09, 2020

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

April 07, 2020

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

April 07, 2020

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

April 03, 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

March 20, 2020

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

March 04, 2020

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

February 27, 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

February 25, 2020

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

February 22, 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

February 21, 2020

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

February 20, 2020

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.